/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Vivani Medical Inc Share Price Today: Live Updates & Key Insights

Vivani Medical Inc share price today is $1.12, up -2.63%. The stock opened at $1.15 against the previous close of $1.14, with an intraday high of $1.15 and low of $1.0781.

Vivani Medical Inc Share Price Chart

style
pb-0

Vivani Medical Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Vivani Medical Inc Share Price Performance

$1.12 -0.0263(-2.63%) VANI at 13 Mar 2026 03:42 PM Biotechnology
Lowest Today 1.0781
Highest Today 1.15
Today’s Open 1.15
Prev. Close 1.14
52 Week High 1.92
52 Week Low 0.91
Day’s Range: Low 1.0781 High 1.15
52-Week Range: Low 0.91 High 1.92
1 day return -
1 Week return -3.87
1 month return -5.5
3 month return -19.2
6 month return -23.63
1 year return +6.19
3 year return +4.2
5 year return -97.49
10 year return -

Vivani Medical Inc Institutional Holdings

Vanguard Group Inc 1.91

Tudor Investment Corp Et AL 1.13

Vanguard Total Stock Mkt Idx Inv 1.05

Tanager Wealth Management LLP 0.91

Vanguard Institutional Extnd Mkt Idx Tr 0.51

Geode Capital Management, LLC 0.44

Commonwealth Equity Services Inc 0.41

Fidelity Extended Market Index 0.31

Monetary Management Group Inc 0.24

Blackrock Extended Mkt Fund CF 0.19

Extended Equity Market Fund K 0.17

State Street Corp 0.16

CI Private Wealth LLC 0.12

EVOKE WEALTH, LLC 0.12

Renaissance Technologies Corp 0.12

BlackRock Inc 0.11

iShares Micro-Cap ETF 0.10

Northern Trust Corp 0.09

Fidelity Total Market Index 0.07

Fidelity Series Total Market Index 0.07

Spartan Extended Market Index Pool F 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

Fidelity Nasdaq Composite Index 0.05

Vanguard Balanced Index Inv 0.04

Spartan Total Market Index Pool G 0.04

Susquehanna International Group, LLP 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Charles Schwab Investment Management Inc 0.04

Schwab Total Stock Market Index 0.04

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

Quadrature Capital Limited 0.02

Citadel Advisors Llc 0.02

Vanguard U.S. Eq Idx £ Acc 0.02

XTX Topco Ltd 0.02

Extended Equity Market Fund M 0.02

UBS Group AG 0.01

SBI Securities Co Ltd 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

Vivani Medical Inc Market Status

Strong Buy: 0

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Vivani Medical Inc Fundamentals

Market Cap 92.57 M

PB Ratio 72.583

PE Ratio 0.0

Enterprise Value 110.68 M

Total Assets 41.56 M

Volume 290308

Vivani Medical Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:260 0.0M, FY20:1000 0.0M, FY19:3379000 3.4M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:130 0.0M, FY20:501000 0.5M, FY19:1227000 1.2M

Annual Net worth FY23:-26910000 -26.9M, FY22:-6537000 -6.5M, FY21:-12132000 -12.1M, FY20:-9279000 -9.3M, FY19:-33592000 -33.6M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-105000 -0.1M, Q2/2025:null 0.0M, Q1/2025:-102000 -0.1M, Q3/2024:null 0.0M, Q2/2024:-100000 -0.1M

Quarterly Net worth Q3/2025:-6530000 -6.5M, Q2/2025:-7144000 -7.1M, Q1/2025:-6302000 -6.3M, Q3/2024:-6041000 -6.0M, Q2/2024:-5356000 -5.4M

About Vivani Medical Inc & investment objective

Company Information Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.

Organisation Biotechnology

Employees 37

Industry Biotechnology

CEO Dr. Adam Mendelsohn Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow